Stifel’s latest report highlights a surge in biotech momentum, driven by M&A activity, easing rates, and renewed investor confidence—featuring RNA therapeutics as a major innovation focus—with select data provided by DealForma. Read it here

Raveena Bhambra tracked the largest licensing and M&A deals of the first half of 2025. DealForma was happy to help. Read it here

Explore Q2 2025 trends in biopharma and medtech venture funding, M&A and licensing deals. Download the latest J.P. Morgan reports for comprehensive insights and analysis – powered by DealForma. Download them here

Chinese biopharma received 28% of global upfront licensing payments through June 2025. Amber Tong, Jinshan Hong, and Spe Chen cover the latest shift in drug development and biopharma deals from China. Biopharma deal data from DealForma. Read it here

Biotech dealmaking remains strong in 2025, fueled by licensing, M&A, and a surge in AI-driven agreements. The article features several DealForma charts that break down these trends across healthcare, therapeutics, and medtech. Read it here

Stifel’s report offers a deep dive into the latest clinical developments, market dynamics, and pipeline innovations in obesity drugs following the June 2025 ADA conference—with select data contributed by DealForma. Read it here

Nature’s article on biotech’s shifting landscape cites DealForma data showing 2025 venture financing nearing $27B, with more money going to fewer, well-funded startups. Read it here

Stifel’s ASCO 2025 recap and oncology market update, incorporating DealForma data, highlights the rise of bispecific and ADC-based therapies, shifting pharma buyer strategies, and China’s growing prominence in oncology licensing and innovation. Read it here

AI drug discovery deals now feature nine‑figure upfronts and billion‑dollar milestones, with DealForma data showing a shift toward biologics, real‑world data, and broader pharma-AI partnerships. Read it here

CNBC uses data from DealForma to report on Pfizer’s and China’s 3SBio’s deal to license cancer drug. Watch the clip here

Using DealForma insights, PharmaShots’ Top 20 Biopharma Deal Terminations of 2024 highlights major partnership cancellations, led by the $4.45B Adaptimmune–Genentech deal. Read it here

In Q1 2025, J.P. Morgan’s biopharma and medtech deal reports—powered by DealForma—highlighted sustained investor interest with $6.7B in biopharma and $3.7B in medtech venture funding, alongside significant licensing and M&A activity, despite a cautious IPO market. Download their analysis